



Docket No.: 6643R5
Customer No.: 030113

#14C
n.m.
11/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Joseph K. Agyin, et al. § Examiner: Delacroix Muirheid, C.
Serial No.: 09/676,032 § Group Art Unit: 1614
Filed: September 29, 2000 §
For: Compounds and Methods for Use
Thereof in the Treatment of Cancer
or Viral Infections §

TECH CENTER 1600/2900

NOV 15 2002

RECEIVED

Commissioner of Patents
Washington, D.C. 20231

Sir:

AMENDMENT; RESPONSE TO OFFICE ACTION
MAILED AUGUST 27, 2002

The present paper is submitted as a complete response to the Official Action mailed August 27, 2002 having a shortened statutory period of response of three months, to and including November 27, 2002. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. No fees are believed due, however, the Commissioner is authorized to deduct any fees under 37 C.F.R. §§ 1.16 to 1.21 that are deemed necessary for the filing of the present document from Haynes and Boone Deposit Account No. 08-1394.

AMENDMENT

In the Specification

At page 16, the paragraph beginning at line 25 is amended, as indicated below and in the marked up version included with this response as Attachment A:

DNA topoisomerase II inhibitors include the following intercalators, such as amsacrine, dactinomycin, daunorubicin, doxorubicin (ADRIAMYCIN®), idarubicin, and mitoxantrone; nonintercalators, such as etoposide and teniposide, for example.

At page 17, the paragraph beginning at line 28 is amended as indicated below:

TAXOL® (paclitaxel) is a preferred chemotherapeutic agent.